Company Profile

ImmunoMedics Inc
Profile last edited on: 12/21/2020            CAGE: 1TSG0

MAb-based treatments for cancer and autoimmune diseases
Year Founded
1982
1st Award Year
1985
Latest Award
2013
Program Status
Inactive (Acquired)
Popularity Index

WikiProfile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

300 The American Road
Morris Plains, NJ 07950
   (973) 605-8200
   info@immunomedics.com
   www.immunomedics.com
Multiple Locations:   
Congressional District:   11
County:   Morris

Public Profile

In October 2020, it was announced that Gilead Sciences - itself an SBIR involved firm in the firm's early days - had completed acquire Immunomedics, Inc. (Nasdaq: IMMU) for a sum of approximately $21 billion in the aggregate. A leader in next-generation antibody-drug conjugate (ADC) technology, Immunomedics is a biopharmaceutical company primarily focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, the firm ceasedtrading that day. ImmunoMedics Inc had developed a number of advanced technologies allowing creatiion of humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics or toxins, in each case to create targeted agents. ImmunoMedics has licensed its product candidate epratuzumab, to UCB S.A. (UCB), for the treatment of all autoimmune disease indications. Epratuzumab’s advanced clinical testing is for the treatment of systemic lupus erythematosus (SLE), and in non-Hodgkin’s lymphoma (NHL). Rights have been retained for epratuzumab in oncology indications, subject to UCB’s buy-in option, and is advancing trials in lymphoma and in childhood acute lymphoblastic leukemia (ALL), in cooperation with National Cancer Institute Study Groups

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
250-500
Revenue Range
20M-50M
VC funded?
Yes
Public/Private
Publicly Traded
Stock Info
NASDAQ : IMMU
IP Holdings
250-500

Awards Distribution by Agency

Key People / Management

  Cynthia L Sullivan -- President

  Kurt Andrews -- Chief Human Resource Officer

  Thomas M Cardillo

  Chien Hsing K Chang

  Brendan Delaney -- CCO

  David M Goldenberg -- Founder, Chief Scientific Officer and Chief Medical Officer

  Serengulam V Govindan

  Gary L Griffiths

  Hans Hansen

  Habibe Karacay

  Shui-On Leung

  Donglin Liu

  William McBride

  Peter Pfreundschuh -- Vice President, Finance and Chief Financial Officer

  Zhengxing Qu

  Edmund A Rossi

  Puja Sapra

  Lisa B Shih

  Dan Shochat

  Robert M Sundoro

  William A Wegener